<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691298</url>
  </required_header>
  <id_info>
    <org_study_id>17-5010-06</org_study_id>
    <nct_id>NCT03691298</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the SUTUREFIX ULTRA and SUTUREFIX CURVED Suture Anchors in Shoulder and Hip Arthroscopic Repair</brief_title>
  <acronym>SuturefixUltra</acronym>
  <official_title>Prospective, Multicenter, Post-Market 1 Year Clinical Follow-up Study to Evaluate Safety and Performance of the SUTUREFIX ULTRA and SUTUREFIX CURVED Suture Anchors in Shoulder and Hip Arthroscopic Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew Orthopaedics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scientific justification is to fulfill post-market clinical requirements in order to&#xD;
      support re-certification of the CE-Mark for this marketed product and to look into safety and&#xD;
      efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shoulder: The superior labrum (fibrous cartilage) and biceps anchor improve joint stability&#xD;
      by acting like a secondary stabilizer to the shoulder. Labral injuries are usually associated&#xD;
      with anterior shoulder dislocation. When conservative treatment fails, such as physical&#xD;
      therapy, strengthening programs, anti-inflammatories and activity modification to improve&#xD;
      symptoms, surgical intervention may be required. Surgical treatments can include simple&#xD;
      debridement (the medical removal of dead damaged or infected tissue), stabilization of the&#xD;
      biceps-labrum complex through repair, or biceps tenodesis where the end of a tendon is joined&#xD;
      surgically to the bone. Outcomes of SLAP (superior labral tear from anterior to posterior)&#xD;
      repairs have been reported good throughout the literature, with reported success rates&#xD;
      ranging from 71-97%.&#xD;
&#xD;
      Hip: The labrum of the hip is a fibrocartilaginous tissue that connects to the bone edge of&#xD;
      the acetabulum (the socket of the hip bone), and deepens the acetabular socket while&#xD;
      extending coverage of the femoral head; it also aids in hip stabilization. The goal of&#xD;
      surgical intervention is to restore normal hip mechanics and treat existing damage. In an&#xD;
      epidemiology study published in 2017, labral pathology was the most common diagnosis at 82%&#xD;
      of the population. Of the 1,124 tears reported, 75.3% were repaired, 13.7% were reconstructed&#xD;
      and 7.2% were debrided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>6 month post-surgery</time_frame>
    <description>Subjects without signs of failure and/or re-intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>12 months post-operative</time_frame>
    <description>Subjects without signs of failure and/or re-intervention</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Instability, Joint</condition>
  <arm_group>
    <arm_group_label>Arthroscopic hip repair</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suturefix Ultra and Suturefix Curved Suture Anchor</intervention_name>
    <description>Fixation device intended to provide secure fixation of soft tissue to bone to stabilize hip</description>
    <arm_group_label>Arthroscopic hip repair</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with hip or shoulder instability&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has consented to participate in the study by signing the EC-approved informed&#xD;
             consent form&#xD;
&#xD;
          -  Subject condition meets proposed indication to SUTUREFIX ULTRA and SUTUREFIX CURVED&#xD;
             Suture Anchor&#xD;
&#xD;
          -  Subject requiring shoulder or hip arthroscopic labral repair surgery from physical&#xD;
             findings, subject symptoms and radiographic finding Hip subjects&#xD;
&#xD;
          -  FAI (Femoroacetabular Impingement) Shoulder subjects&#xD;
&#xD;
          -  Subject with a history of recurrent dislocation/subluxation of the shoulder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in the treatment period of another clinical trial within thirty (30)&#xD;
             days of Visit 1 (pre-operative)&#xD;
&#xD;
          -  Women who are pregnant, nursing, or of child-bearing potential who are not utilizing&#xD;
             highly effective birth control measures&#xD;
&#xD;
          -  Contraindications or hypersensitivity to the use of the SUTUREFIX ULTRA and/or&#xD;
             SUTUREFIX CURVED Suture Anchor, or their components (e.g. silicone, polyester). Where&#xD;
             material sensitivity is suspected, appropriate tests should be performed and&#xD;
             sensitivity ruled out prior to implantation&#xD;
&#xD;
          -  Pathological conditions of bone, such as cystic changes or severe osteopenia, which&#xD;
             would compromise secure anchor fixation&#xD;
&#xD;
          -  Pathological conditions in the soft tissues to be attached that would impair secure&#xD;
             fixation by suture&#xD;
&#xD;
          -  Comminuted bone surface, which would compromise secure anchor fixation Hip subjects&#xD;
             Dysplasia latera/central less than 20° Shoulder subjects&#xD;
&#xD;
          -  Glenoid and/or humeral bone loss considered excessive by the treating orthopaedic&#xD;
             surgeon&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktor Zsuffa, MLaw</last_name>
    <role>Study Chair</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viktor Zsuffa, MLaw</last_name>
    <phone>+41 41 766 22 67</phone>
    <email>viktor.zsuffa@smith-nephew.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CPH Privathospital</name>
      <address>
        <city>Farum</city>
        <zip>3520</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>45 702 18000</phone>
      <email>sorenwinge@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Soren Winge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pihlajalinna Turku Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+358 10 312 178</phone>
      <email>matti.seppanen@pihlajalinna.fi</email>
    </contact>
    <investigator>
      <last_name>Matti Seppänen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 06 58701</phone>
      <email>marcodoc@me.com</email>
    </contact>
    <investigator>
      <last_name>Marco Spoliti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asepeyo Hospital Sant Cugat</name>
      <address>
        <city>Sant Cugat del Vallès</city>
        <state>Barcelona</state>
        <zip>08174</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordi Ardévol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 91 5495544</phone>
      <email>ecalvo@fjd.es</email>
    </contact>
    <investigator>
      <last_name>Emilio Calvo Crespo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Cosham</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 792 107 8923</phone>
      <email>langdowns@btinternet.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Langdown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fortius Clinic</name>
      <address>
        <city>London</city>
        <zip>W1H 6EQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 203 195 2333</phone>
      <email>andrew.wallace@fortiusclinic.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Wallace</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suturefix</keyword>
  <keyword>hip instability</keyword>
  <keyword>shoulder instability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Instability</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

